Mi az ára Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics, Inc. (PSTX) ára $9.50

Mi a Poseida Therapeutics, Inc. (PSTX piaci tőkésítése)

Poseida Therapeutics, Inc. piaci tőkésítése (PSTX) $819.52M

Poseida Therapeutics, Inc. (PSTX) P/B mutató

Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.

Év	P/B arány	Változtassa meg
2026 (TTM)	8.26	182.94%
2023	2.92	43.83%
2022	2.03	-25.05%
2021	2.71	10.84%
2020	2.45	-159.95%
2019	-4.08	-43.25%
2018	-7.19	-60.46%
2017	-18.18	-132.79%
2016	55.46	0.00%

Év

P/B arány

Változtassa meg

2026 (TTM)

8.26

182.94%

2023

2.92

43.83%

2022

2.03

-25.05%

2021

2.71

10.84%

2020

2.45

-159.95%

2019

-4.08

-43.25%

2018

-7.19

-60.46%

2017

-18.18

-132.79%

2016

55.46

0.00%

Vállalat	P/B arány	P/B arány különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-23.24%	US
Argenx SE ARGX.US	6.2413	-24.46%	NL
CSL Limited CSL.AX	2.5054	-69.67%	AU
Moderna, Inc. MRNA.US	3.7087	-55.11%	US
Lonza Group AG LONN.SW	-	-	CH

Vállalat

P/B arány

P/B arány különbség

Ország